Home LiteratureArticle Details
PMID: 9691092 Published · ppublish English Comparative Study Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Molecular analysis of the role of the group A streptococcal cysteine protease, hyaluronic acid capsule, and M protein in a murine model of human invasive soft-tissue infection.

The Journal of clinical investigation ·Vol. 102 ·No. 3 ·1998-08-01 ·Pages 550-60

Ashbaugh CD, Warren HB, Carey VJ, Wessels MR

Abstract

Human invasive soft-tissue infections caused by group A Streptococcus are associated with significant morbidity and mortality. To investigate the pathogenesis of these serious infections, we characterized the host response to bacterial challenge with an M-type 3 isolate recovered from a patient with necrotizing fasciitis, or with isogenic gene replacement mutants deficient in cysteine protease, hyaluronic acid capsule, or M protein in a murine model of human invasive soft-tissue infection. Animals challenged with the wild-type or cysteine protease-deficient strain developed spreading tissue necrosis at the site of inoculation, became bacteremic, and subsequently died. Histopathologic examination of the necrotic lesion revealed bacteria throughout inflamed subcutaneous tissue. Arterioles and venules in the subcutaneous layer were thrombosed and the overlying tissue was infarcted. In contrast, animals challenged with either an acapsular or M protein-deficient mutant developed a focal area of tissue swelling at the site of inoculation without necrosis or subsequent systemic disease. Histopathologic examination of the soft-tissue lesion demonstrated bacteria confined within a well-formed subcutaneous abscess. We conclude that the group A streptococcal hyaluronic acid capsule and M protein, but not the cysteine protease, are critical for the development of tissue necrosis, secondary bacteremia, and lethal infection in a murine model of human necrotizing fasciitis.

MeSH Terms
Abscess/microbiology,pathology Animals Antigens, Bacterial Bacteremia/microbiology,pathology Bacterial Capsules/physiology Bacterial Outer Membrane Proteins Bacterial Proteins/physiology Carrier Proteins Child Exotoxins/deficiency,genetics,physiology Fasciitis, Necrotizing/microbiology,pathology Female Humans Hyaluronic Acid/physiology Membrane Proteins Mice Phagocytosis Streptococcal Infections/microbiology,pathology Streptococcus pyogenes/enzymology,genetics,isolation & purification,pathogenicity Virulence
Chemicals
Antigens, Bacterial Bacterial Outer Membrane Proteins Bacterial Proteins Carrier Proteins Exotoxins Membrane Proteins SpeA protein, Streptococcus pyogenes erythrogenic toxin streptococcal M protein Hyaluronic Acid
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Ashbaugh C D
Channing Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA. cashbaugh@channing.harvard.edu
Warren H B
Carey V J
Wessels M R
References (37)
37 references, click to expand
  1. Role of M protein in pharyngeal colonization by group A streptococci in rats.
    Infect Immun. 1993 Jun;61(6):2277-83 PMID: 8500869
  2. Geographic and temporal distribution and molecular characterization of two highly pathogenic clones of Streptococcus pyogenes expressing allelic variants of pyrogenic exotoxin A (Scarlet fever toxin).
    J Infect Dis. 1993 Feb;167(2):337-46 PMID: 8093623
  3. An M protein with a single C repeat prevents phagocytosis of Streptococcus pyogenes: use of a temperature-sensitive shuttle vector to deliver homologous sequences to the chromosome of S. pyogenes.
    Mol Microbiol. 1993 May;8(5):809-19 PMID: 8355608
  4. Molecular cloning, identification, and sequence of the hyaluronan synthase gene from group A Streptococcus pyogenes.
    J Biol Chem. 1993 Sep 15;268(26):19181-4 PMID: 8366070
  5. Molecular characterization of hasA from an operon required for hyaluronic acid synthesis in group A streptococci.
    J Biol Chem. 1994 Jan 7;269(1):169-75 PMID: 8276791
  6. Effects on virulence of mutations in a locus essential for hyaluronic acid capsule expression in group A streptococci.
    Infect Immun. 1994 Feb;62(2):433-41 PMID: 8300204
  7. Critical role of the group A streptococcal capsule in pharyngeal colonization and infection in mice.
    Proc Natl Acad Sci U S A. 1994 Dec 6;91(25):12238-42 PMID: 7991612
  8. Streptococcal cysteine proteinase releases biologically active fragments of streptococcal surface proteins.
    J Biol Chem. 1995 Apr 28;270(17):9862-7 PMID: 7730368
  9. Molecular characterization of hasC from an operon required for hyaluronic acid synthesis in group A streptococci. Demonstration of UDP-glucose pyrophosphorylase activity.
    J Biol Chem. 1995 Dec 1;270(48):28676-80 PMID: 7499387
  10. C5a peptidase alters clearance and trafficking of group A streptococci by infected mice.
    Infect Immun. 1996 Feb;64(2):503-10 PMID: 8550199
  11. Genetic and phenotypic diversity among isolates of Streptococcus pyogenes from invasive infections.
    J Infect Dis. 1996 Apr;173(4):901-8 PMID: 8603969
  12. Substitution of cysteine 192 in a highly conserved Streptococcus pyogenes extracellular cysteine protease (interleukin 1beta convertase) alters proteolytic activity and ablates zymogen processing.
    Infect Immun. 1996 Jun;64(6):1913-7 PMID: 8675287
  13. Invasive group A streptococcal infections in Ontario, Canada. Ontario Group A Streptococcal Study Group.
    N Engl J Med. 1996 Aug 22;335(8):547-54 PMID: 8684408
  14. Recombinant, octavalent group A streptococcal M protein vaccine.
    Vaccine. 1996 Jul;14(10):944-8 PMID: 8873386
  15. Activation of a 66-kilodalton human endothelial cell matrix metalloprotease by Streptococcus pyogenes extracellular cysteine protease.
    Infect Immun. 1996 Nov;64(11):4744-50 PMID: 8890235
  16. Hyaluronic acid capsule and the role of streptococcal entry into keratinocytes in invasive skin infection.
    J Clin Invest. 1996 Nov 1;98(9):1954-8 PMID: 8903312
  17. Relative contributions of hyaluronic acid capsule and M protein to virulence in a mucoid strain of the group A Streptococcus.
    Infect Immun. 1997 Jan;65(1):64-71 PMID: 8975893
  18. Role of putative virulence factors of Streptococcus pyogenes in mouse models of long-term throat colonization and pneumonia.
    Infect Immun. 1997 Apr;65(4):1422-30 PMID: 9119483
  19. Inactivation of Streptococcus pyogenes extracellular cysteine protease significantly decreases mouse lethality of serotype M3 and M49 strains.
    J Clin Invest. 1997 Jun 1;99(11):2574-80 PMID: 9169486
  20. Genetic inactivation of an extracellular cysteine protease (SpeB) expressed by Streptococcus pyogenes decreases resistance to phagocytosis and dissemination to organs.
    Infect Immun. 1998 Feb;66(2):771-6 PMID: 9453640
  21. Differentiation of group A streptococci with a common R antigen into three serological types, with special reference to the bactericidal test.
    J Exp Med. 1957 Oct 1;106(4):525-44 PMID: 13475611
  22. Current knowledge of type-specific M antigens of group A streptococci.
    J Immunol. 1962 Sep;89:307-13 PMID: 14461914
  23. Mechanism of action of the group A streptococcal C5a inactivator.
    Proc Natl Acad Sci U S A. 1985 Dec;82(23):8144-8 PMID: 3906656
  24. Streptococcal necrotising fasciitis: comparison between histological and clinical features.
    J Clin Pathol. 1987 Mar;40(3):335-41 PMID: 3558868
  25. Clinical and bacteriologic observations of a toxic shock-like syndrome due to Streptococcus pyogenes.
    N Engl J Med. 1987 Jul 16;317(3):146-9 PMID: 3299086
  26. In vivo Streptococcus pyogenes C5a peptidase activity: analysis using transposon- and nitrosoguanidine-induced mutants.
    J Infect Dis. 1987 Sep;156(3):495-504 PMID: 3039012
  27. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A.
    N Engl J Med. 1989 Jul 6;321(1):1-7 PMID: 2659990
  28. Nucleotide sequence of the streptococcal pyrogenic exotoxin type B gene and relationship between the toxin and the streptococcal proteinase precursor.
    J Bacteriol. 1990 Aug;172(8):4536-42 PMID: 2198264
  29. Role of M protein in adherence of group A streptococci.
    Infect Immun. 1991 May;59(5):1811-7 PMID: 2019444
  30. Construction of versatile low-copy-number vectors for cloning, sequencing and gene expression in Escherichia coli.
    Gene. 1991 Apr;100:195-9 PMID: 2055470
  31. Outbreak of group A streptococcus septicemia in children. Clinical, epidemiologic, and microbiological correlates.
    JAMA. 1991 Jul 24-31;266(4):533-7 PMID: 2061980
  32. Hyaluronic acid capsule is a virulence factor for mucoid group A streptococci.
    Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8317-21 PMID: 1656437
  33. Genetic manipulation of pathogenic streptococci.
    Methods Enzymol. 1991;204:556-86 PMID: 1658571
  34. Clonal basis for resurgence of serious Streptococcus pyogenes disease in the 1980s.
    Lancet. 1992 Feb 29;339(8792):518-21 PMID: 1346879
  35. Streptococcal C5a peptidase is a highly specific endopeptidase.
    Infect Immun. 1992 Dec;60(12):5219-23 PMID: 1452354
  36. Introduction of the emm6 gene into an emm-deleted strain of Streptococcus pyogenes restores its ability to resist phagocytosis.
    Res Microbiol. 1992 Jul-Aug;143(6):549-58 PMID: 1475516
  37. Association of phenotypic and genotypic characteristics of invasive Streptococcus pyogenes isolates with clinical components of streptococcal toxic shock syndrome.
    Infect Immun. 1993 Aug;61(8):3369-74 PMID: 8335368
Article Info
Journal
The Journal of clinical investigation
Abbr.
J Clin Invest
ISSN
0021-9738
Published
1998-08-01
Pages
550-60
Language
English
Region
United States
NLM ID
7802877
PMCID
PMC508916
Subset
IM
Grants
NIAID NIH HHS · AI01343 · United States
NIAID NIH HHS · AI29952 · United States
NIAID NIH HHS · AI75236 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com